Another approach involves targeting upstream regulators of CCL2: F-box and WD repeat domain-containing protein 7 (FBXW7), an E3 ubiquitin ligase in the gut, promotes Ccl2 and Ccl7 expression, exacerbating inflammatory bowel diseases (IBDs). Here, CCL2 is linked to inflammatory bowel disease.